-
The pharmaceutical stock opened its subscription today and is expected to have a net profit of more than $380 million for the full year
Time of Update: 2022-12-30
90%, and it is expected that the company's net cash flow from operating activities after the virtual conversion of notes to cash will exceed RMB71 billion in 2022, with high profit quality.
-
Pharmaceutical commercial stocks rebounded and will continue to maintain a rapid growth trend
Time of Update: 2022-12-30
82 billion yuan in the first three quarters of this year (+20%); Achieved net profit attributable to owners of RMB920 million (+12.
82 billion yuan in the first three quarters of this year (+20%); Achieved net profit attributable to owners of RMB920 million (+12.
-
This 5-day, 3-board pharmaceutical stock was fined more than the company's net profit in the first three quarters because of monopoly
Time of Update: 2022-12-30
News on December 13, Northeast Pharmaceutical announced that the company recently received the "Administrative Penalty Notice" issued by the Liaoning Provincial Administration for Market Regulation, because the company violated the anti-monopoly law by selling L-carnitine APIs at unfairly high prices between November 2018 and June 2019, and the company was fined a total of 133 million yuan.
-
Guangshengtang 20cm up limit, Chinese medicine 2 plates... On the 16th, the pharmaceutical sector became active again
Time of Update: 2022-12-30
【Pharmaceutical Network Pharmaceutical Stock Market】 On December 16, the intraday Chinese medicine sector was active again, Guangshengtang hit the 20cm price limit, China Pharmaceutical achieved 2 con
-
Price gouging, bundling? Wenzhou urban interview warns a large number of pharmaceutical companies!
Time of Update: 2022-12-30
In order to ensure the overall order of the epidemic-related pharmaceutical and equipment market during the adjustment and optimization of epidemic prevention and control policies, the Ouhai District
-
The pharmaceutical sector has changed! Lingkang Pharmaceutical, Yisheng Pharmaceutical, etc
Time of Update: 2022-12-30
On the news, Xinhua Pharmaceutical said on the interactive platform on December 21 that the company is actively cooperating with the relevant requirements of the national epidemic prevention policy, working overtime to produce urgently needed drugs in the market and making every effort to ensure market supply.
-
What are the symptoms of people who re-yang People who re-yang generally return to the yang within a few days
Time of Update: 2022-12-30
4. Eye symptoms:Patients with novel coronavirus pneumonia may experience eye discomfort, and common eye symptoms include itchy eyes, eye pain, conjunctival hyperemia, conjunctival edema, etc.
4. Eye symptoms:Patients with novel coronavirus pneumonia may experience eye discomfort, and common eye symptoms include itchy eyes, eye pain, conjunctival hyperemia, conjunctival edema, etc.
-
How virulent is the Omicron variant? How is it treated?
Time of Update: 2022-12-30
A: With the mutation of the virus, as well as the popularization of vaccination and the accumulation of experience in prevention and control, the hospitalization, severe disease rate and case fatality rate caused by Omicron are all greatly reduced.
-
The pharmaceutical sector continues to diverge! Northeast Pharmaceutical 6 days 4 boards, Shu Taishen and other bucked the trend
Time of Update: 2022-12-30
Northeast Pharmaceutical, which recently attracted attention due to "2 yuan and 20 tablets of antipyretic drugs", rose again after the opening on December 20, achieving "6 days and 4 boards", as of the close of the day, the stock rose 10.
-
This pharmaceutical stock was surveyed by more than 100 institutions in 2 days!
Time of Update: 2022-12-30
In recent years, thanks to the significant increase in sales of protective products in medical consumables, the company's performance has also ushered in explosive growth.
In recent years, thanks to the significant increase in sales of protective products in medical consumables, the company's performance has also ushered in explosive growth.
-
Xu Haoyu: Life and health enterprises have the responsibility to establish a healthy and civilized concept
Time of Update: 2022-12-30
Boao, November 28, Xinhuanet (Wu Qilong) From November 25 to 28, the 2022 Boao Forum for Chinese Entrepreneurs was held in Boao, Hainan. Xu Haoyu, secretary of the party committee, chairman and gener
-
License-in "not fragrant"? Another IPO of the science and technology innovation board of pharmaceutical companies was pressed the "pause button"
Time of Update: 2022-12-30
【Pharmaceutical Network Market Analysis】In recent years, with the normalization of centralized procurement, medical insurance control fees and other policies, the domestic pharmaceutical industry has
-
Up more than 14% in early trading! This pharmaceutical stock has earned enough eyeballs because of "ibuprofen"
Time of Update: 2022-12-30
In addition, on December 12, Shisi Pharmaceutical Group released news that its products such as Arbidol and azithromycin were listed as domestic anti-epidemic household backup drugs.
In addition, on December 12, Shisi Pharmaceutical Group released news that its products such as Arbidol and azithromycin were listed as domestic anti-epidemic household backup drugs.
-
Ascletis Pharmaceutical, Clover and other B-class pharmaceutical stocks strengthened
Time of Update: 2022-12-30
According to the data, Clover is a biotechnology company in the clinical trial stage, committed to developing novel vaccine and biotherapeutic product candidates for infectious diseases, cancer and autoimmune diseases.
-
In 2023, the opportunities in the pharmaceutical sector look at two keywords
Time of Update: 2022-12-30
On the one hand, "anti-epidemic" related products and anti-cold drugs and their industrial chain are still expected to benefit, including anti-cold drugs (including traditional Chinese medicine) with high performance certainty, retail pharmacies, household equipment such as oxygen generators, antigen testing, etc.
-
Investment and financing in the field of medicine and biology are active, and enterprise innovation will usher in accelerated development
Time of Update: 2022-12-30
Prior to this, Guosen Pharmaceutical also announced the completion of a series B+ financing of nearly 100 million yuan, after the completion of this round of financing, the company will continue to focus on and deepen the clinical research of innovative drugs in cutting-edge pipelines, deepen business and technology, and continue to highlight the advantages in the field of cell and gene therapy (CGT).
-
Many pharmaceutical companies said that they will increase production capacity, will the demand for upstream equipment usher in growth?
Time of Update: 2022-12-30
【Pharmaceutical Network Market Analysis】Recently, under the prospect of ibuprofen and other antipyretic and analgesic drugs setting off a rush to buy or even some products in short supply, the production capacity of related pharmaceutical companies has also attracted market attention.
-
Tens of billions of markets to be broken! The popularity of "orphan drugs" in China continues to rise
Time of Update: 2022-12-30
In order to encourage domestic pharmaceutical companies to increase the research and development and production of rare disease drugs, in recent years, national government departments have successively issued a series of incentive policies.
-
Establish a "white list" management system to promote pharmaceutical companies to expand production and increase the supply of key drug markets
Time of Update: 2022-12-30
Jiao Yahui, Director of the Department of Medical Affairs of the National Health Commission:In response to the shortage of drugs in some regions caused by the recent increase in the number of patients and the surge in drug demand, the relevant person in charge of the Ministry of Industry and Information Technology introduced that enterprises have been promoted to rapidly stabilize production, expand capacity and expand production, and increase the supply of key drug markets.
-
The domestic pharmaceutical equipment industry is growing against the trend, and its revenue may exceed 25 billion yuan in 2023
Time of Update: 2022-12-30
Data show that in recent years, the sales of the pharmaceutical equipment industry have shown a gradual improvement trend, and it is predicted that the sales of this market will reach 23.
